Pomdoctor Limited (POM) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Pomdoctor Limited (POM) trades at $1.02 with AI Score 41/100 (Grade C). Pomdoctor Limited operates an online B2C portal for pharmaceutical products and develops an online medical services platform for chronic diseases in China. Market cap: $6.91M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for POM: POM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates POM against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
POM: 2/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Pomdoctor Limited (POM) Healthcare & Pipeline Overview
Pomdoctor Limited, based in China, operates a B2C online portal for pharmaceutical products and a platform for chronic disease management. The company connects patients, doctors, pharmacies, and suppliers through its internet hospital and pharmaceutical supply chain. It focuses on chronic disease management and pharmaceutical services within the Chinese healthcare market.
What Is the Investment Thesis for POM?
Pomdoctor Limited presents a focused approach to addressing chronic disease management and pharmaceutical access in China through its online platform. The company's integrated internet hospital and pharmaceutical supply chain model aims to connect patients, doctors, and suppliers, potentially streamlining healthcare delivery. However, the company's negative profit margin of -41.9% raises concerns about its financial sustainability and operational efficiency. Key growth catalysts include expanding its user base and service offerings within the chronic disease management space. Investors should closely monitor the company's ability to improve profitability and navigate the competitive landscape of online healthcare platforms in China. The company's beta of -7.15 suggests an inverse correlation with the market, which may appeal to risk-averse investors.
Based on FMP financials and quantitative analysis
POM Key Highlights
Market capitalization of $6.91M indicates a small-cap company with potential for growth but also higher volatility.
- Negative profit margin of -41.9% signals significant challenges in achieving profitability and efficient cost management.
- Gross margin of 13.9% suggests some ability to generate revenue above the cost of goods sold, but leaves limited room for operating expenses.
- The company operates an online B2C portal for pharmaceutical products and develops an online medical services platform for chronic diseases in China.
- Beta of -7.15 indicates a strong inverse correlation with the market, offering potential diversification benefits.
Who Are POM's Competitors?
POM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ERAS Erasca, Inc. | $17.08 | -5.48% | $5.93B | 66 |
| HEWA HealthWarehouse.com, Inc. | $0.11 | +0.00% | $6.29M | 55 |
| YI 111, Inc. | $3.44 | -1.99% | $30.1M | 44 |
| MYCOF Noveris Health Sciences Inc. | $0.73 | +0.00% | $42.7M | 48 |
| LFLY Leafly Holdings, Inc. | $37.00 | +0.00% | $115M | 50 |
| HITI High Tide Inc. | $2.42 | -1.42% | $213M | 47 |
| BJTRF Beijing Tong Ren Tang Chinese Medicine Company Limited | $0.65 | +0.00% | $543M | 55 |
| CGEM Cullinan Therapeutics, Inc. | $21.38 | -5.06% | $1.31B | 57 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are POM's Key Strengths?
Online platform for pharmaceutical sales and chronic disease management.
- Integrated internet hospital and pharmaceutical supply chain.
- Focus on the growing chronic disease market in China.
What Are POM's Weaknesses?
Negative profit margin indicates financial challenges.
- Limited information available on market share and competitive positioning.
- Reliance on the Chinese regulatory environment.
What Could Drive POM Stock Higher?
Potential regulatory approvals for new pharmaceutical products or online healthcare services.
- Expansion of partnerships with pharmacies and hospitals to broaden service reach.
- Increasing adoption of online healthcare services in China due to growing internet penetration and healthcare awareness.
What Are the Key Risks for POM?
Changes in regulations governing online healthcare and pharmaceutical sales in China.
- Increased competition from established online healthcare platforms and traditional pharmaceutical companies.
- Negative profit margin and challenges in achieving financial sustainability.
- Cybersecurity breaches and data privacy concerns related to online platform operations.
What Are the Growth Opportunities for POM?
- Expansion of Chronic Disease Management Services: Pomdoctor can expand its chronic disease management services by incorporating more specialized programs for specific conditions like diabetes, hypertension, and cardiovascular diseases. This involves developing personalized treatment plans, remote monitoring capabilities, and educational resources for patients. The market for chronic disease management in China is substantial, driven by an aging population and increasing prevalence of lifestyle-related diseases. Success hinges on regulatory compliance and partnerships with healthcare providers.
- Strategic Partnerships with Pharmacies and Hospitals: Collaborating with established pharmacies and hospitals can significantly enhance Pomdoctor's reach and credibility. These partnerships can facilitate the integration of online and offline services, allowing patients to access medication and consultations more conveniently. The Chinese healthcare system is heavily reliant on hospitals and pharmacies, making these partnerships crucial for market penetration. This strategy can improve patient trust and expand the company's service offerings.
- Development of AI-Powered Diagnostic Tools: Integrating artificial intelligence (AI) into its platform can enable Pomdoctor to offer more accurate and efficient diagnostic services. AI-powered tools can analyze patient data, identify potential health risks, and provide personalized recommendations. The AI in healthcare market is growing rapidly, driven by advancements in machine learning and increasing availability of healthcare data. This can improve patient outcomes and reduce healthcare costs.
- Geographic Expansion within China: Pomdoctor can expand its services to additional regions within China, targeting areas with high demand for online healthcare services and limited access to traditional healthcare facilities. This involves establishing local partnerships, adapting its platform to local languages and customs, and navigating regional regulatory requirements. The Chinese market is vast and diverse, offering significant opportunities for geographic expansion. This can increase the company's market share and revenue streams.
- Integration of Telemedicine Services: Incorporating telemedicine services into its platform can allow Pomdoctor to offer remote consultations and virtual care to patients. This can improve access to healthcare services, particularly for patients in rural areas or those with mobility issues. The telemedicine market is growing rapidly, driven by advancements in technology and increasing acceptance of remote healthcare. This can improve patient satisfaction and expand the company's service offerings.
What Are POM's Competitive Advantages?
- Established online platform for pharmaceutical sales and chronic disease management in China.
- Integrated internet hospital and pharmaceutical supply chain creates a comprehensive ecosystem.
- Focus on chronic disease management addresses a significant and growing need in the Chinese healthcare market.
What Does POM Do?
Founded in 2010 and headquartered in Guangzhou, China, Pomdoctor Limited operates as a healthcare company focused on chronic disease management and pharmaceutical services. The company has established an online B2C portal to facilitate the sale of pharmaceutical products directly to consumers. Pomdoctor has developed an online medical services platform designed to improve the management of chronic diseases within China. This platform connects patients with doctors and provides access to a range of pharmaceutical products. Pomdoctor's business model is centered around its internet hospital and pharmaceutical supply chain. This integrated approach connects various stakeholders in the healthcare ecosystem, including users, pharmacies, suppliers, medical professionals, and other healthcare participants. The company's platform offers a suite of medical services, facilitating interactions between patients and doctors, and streamlining the process of obtaining pharmaceutical products. By focusing on chronic disease management, Pomdoctor aims to address a significant and growing need within the Chinese healthcare market, leveraging technology to improve access to care and medication.
What Products and Services Does POM Offer?
- Operates an online B2C portal for selling pharmaceutical products directly to consumers.
- Develops and manages an online medical services platform focused on chronic diseases in China.
- Connects patients with doctors through its internet hospital platform.
- Manages a pharmaceutical supply chain, linking users, pharmacies, suppliers, and medical professionals.
- Offers a platform for medical services, facilitating interactions between patients and doctors.
- Focuses on chronic disease management and pharmaceutical services.
How Does POM Make Money?
- Generates revenue through the sale of pharmaceutical products via its online B2C portal.
- Provides a platform for medical services, potentially charging fees for consultations or subscriptions.
- Manages a pharmaceutical supply chain, earning revenue from distribution and logistics.
What Industry Does POM Operate In?
Pomdoctor Limited operates within the rapidly evolving Chinese healthcare market, which is experiencing significant growth in online medical services and pharmaceutical sales. The increasing prevalence of chronic diseases in China is driving demand for effective management solutions and accessible healthcare services. The competitive landscape includes established online healthcare platforms and traditional pharmaceutical companies, requiring Pomdoctor to differentiate itself through specialized services and strategic partnerships. The market is also subject to evolving regulations and policies governing online healthcare and pharmaceutical sales in China.
Who Are POM's Key Customers?
- Patients seeking pharmaceutical products online.
- Individuals managing chronic diseases who require ongoing medical support.
- Pharmacies and suppliers participating in the company's supply chain.
Company Profile
Pomdoctor Limited operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Guangzhou, CN. The company is led by CEO Zhenyang Shi. POM has traded publicly since 2025.
POM Valuation & Market Position
With a $6.91M market cap, Pomdoctor Limited sits in the micro-cap segment of the market. Relative to its peer group, POM's quantitative score of 41/100 is below the peer average of 53/100.
Key Financial Metrics
Return on equity for Pomdoctor Limited stands at 6.5%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -26.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.21 means current liabilities exceed short-term assets, a liquidity point worth watching.
POM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Insiders seem confident; recent buying activity suggests they believe in Pomdoctor's long-term prospects.
- The community's generally optimistic about their new product line; buzz is building.
- Market perception is shifting; Pomdoctor is increasingly seen as an innovator, not just another player.
- Positive developments in their sector are lifting all boats, and Pomdoctor is riding the wave.
Bear Case
- Insider selling, even if small, can signal concerns about the company's future.
- The community's also worried about increased competition; new entrants are putting pressure on Pomdoctor.
- Market perception is that Pomdoctor is overvalued compared to its peers; could be due for a correction.
- Recent regulatory changes could negatively impact Pomdoctor's operations; uncertainty is high.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
POM Latest News
-
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga · Aug 10, 2026
-
12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga · Jul 24, 2026
-
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga · Jul 21, 2026
-
12 Health Care Stocks Moving In Monday's Intraday Session
benzinga · Jul 20, 2026
POM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for POM.
Price Targets
Wall Street price target analysis for POM.
POM MoonshotScore
What does this score mean?
The MoonshotScore rates POM 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest News
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Monday's Intraday Session
Leadership: Zhenyang Shi
CEO
Zhenyang Shi is the CEO of Pomdoctor Limited, leading a team of 156 employees. Details regarding Mr. Shi's prior experience and educational background are not available. As CEO, he is responsible for the strategic direction and overall performance of the company, focusing on expanding its online B2C portal for pharmaceutical products and developing its online medical services platform for chronic diseases in China.
Track Record: Information on Zhenyang Shi's specific achievements and strategic decisions at Pomdoctor Limited is not available. His leadership is focused on connecting patients to doctors and pharmaceutical products through the company's internet hospital and pharmaceutical supply chain platform. The company's current financial performance, including a negative profit margin, presents a challenge for his leadership.
Common Questions About POM (Healthcare)
What does the AI Score mean for POM?
POM holds an AI Score of 41/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Pomdoctor Limited operates an online B2C portal for pharmaceutical products and develops an online medical services platform for chronic diseases in China. The company connects patients to doctors …
What does POMDOCTOR Ltd do?
Pomdoctor Limited operates primarily in China, focusing on providing online pharmaceutical sales and chronic disease management services. The company's core business revolves around its online B2C portal, which allows consumers to purchase pharmaceutical products directly. Additionally, Pomdoctor has developed an online medical services platform specifically designed for chronic disease management.
What do analysts say about POM stock?
Analyst coverage of Pomdoctor Limited (POM) is limited due to its small market capitalization and relatively recent entry into the public markets. Key valuation metrics, such as price-to-earnings ratio, are not applicable due to the company's current negative profitability.
What are the main risks for POM?
Pomdoctor Limited faces several key risks, including regulatory uncertainties in the Chinese online healthcare market, intense competition from larger and more established players, and the challenge of achieving profitability. Changes in regulations governing online pharmaceutical sales and data privacy could significantly impact the company's operations.
What are the key factors to evaluate for POM?
Pomdoctor Limited (POM) holds an AI score of 41/100 (low). Pomdoctor Limited presents a focused approach to addressing chronic disease management and pharmaceutical access in China through its online platform. Not financial advice.
How frequently does POM data refresh on this page?
POM's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven POM's recent stock price performance?
Pomdoctor Limited (POM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Online platform for pharmaceutical sales and chronic disease management. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider POM overvalued or undervalued right now?
Pomdoctor Limited (POM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research POM before investing?
Before investing in Pomdoctor Limited (POM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for in-depth analysis.
- Information on CEO track record is limited.
- Analysis based on publicly available information and AI insights.